



**The Clatterbridge  
Cancer Centre**  
NHS Foundation Trust

Clatterbridge Road  
Bebington  
Wirral  
CH63 4JY

Tel: 0151 556 5000  
Web: [www.clatterbridgecc.nhs.uk](http://www.clatterbridgecc.nhs.uk)

Date: 11 August 2022

**Re: Freedom of Information Request**  
**Ref: 256-2022**

Thank you for your email dated the 21/07/2022, requesting information in relation to Radium-223 dichloride.

The information you require is as follows:

**Question 1**

**Please complete the table below:**

<b>Radium-223 dichloride service</b>	
<b>Is radium-223 dichloride offered in your trust as a treatment for prostate cancer? (y/n)</b>	<b>Y</b>
<b>If yes, please list the indications for which it is used in your trust?</b>	<ul style="list-style-type: none"><li>- <b>Monotherapy or combination with a LHRH analogue for the treatment of patients who have metastatic hormone-relapsed prostate cancer (mHRPC), symptomatic bones metastases and no known visceral metastases.</b></li><li>- <b>Disease progression after at least two prior lines of systemic therapy (excluding LHRH analogues) or ineligible for any systemic mHRPC treatment.</b></li><li>- <b>Performance status 0-2</b></li><li>- <b>ARSAC certificate holder must approve treatment on Meditech</b></li></ul>

## Question 2

Please detail the number of patients that are treated with radium-223 dichloride in your trust:

<b>Patient numbers</b>	
Number of prostate cancer patients completing treatment with radium-223 dichloride per year	33 (Based on patients received radium223 between Apr 21– March 22, either patients completed 6 cycles or patients had no further cycles during Apr - July 2022)
Number of prostate cancer patients initiating radium-223 dichloride treatment per year	25 (patient started cycle during Apr – March 2022)
What is the average number of cycles administered per patient in your service?	4.7 (155 cycles given for the 33 patients above)
What is the waiting time before patients can receive radium-223 dichloride?	24 (23.52) days (Date decision to treat date – Treatment start for the 25 patient above)
How many patients are initiated with cabazitaxel per year in your trust?	32 (patient started during Apr – March 2022)

## Question 3

In what department is molecular radiotherapy provided in your trust?

<b>Administration</b>	<b>Radium-223 dichloride</b>	<b>177Lutetium based radioligand therapy for neuroendocrine tumours</b>
<b>Nuclear Medicine</b>	Y	N/A
<b>Medical Physics</b>		N/A
<b>Radiotherapy</b>		N/A
<b>Oncology</b>		N/A
<b>Urology</b>		N/A
<b>Other</b>		N/A
<b>N/A</b>		N/A

#### Question 4

What codes are associated with molecular radiotherapy administration in your trust?

NHS codes	HRG	OPCS code
Radium-223 dichloride	RN52Z	X65.7

#### Question 5

Please complete the table below:

Who performs the administration of the treatment?	Radium-223 dichloride	177Lutetium based radioligand therapy for neuroendocrine tumours
CNS		N/A
Technician		N/A
NM nurse		N/A
NM physicist		N/A
NM Consultant		N/A
Oncologist		N/A
Other (please state)	Nuclear Medicine Radiographers	N/A

#### Question 6

Who holds the ARSAC licence in your trust?

Administration	(y/n)	Radium-223 dichloride	177Lutetium based radioligand therapy for neuroendocrine tumours
Nuclear Medicine consultant			N/A
Clinical Oncologist		Y	N/A
Radiologist			N/A
Other (please state speciality)			

#### Question 7

Do you provide Radioactive Waste Advisory, Radiation Protection Advisory and Medical Physics Expert services in your trust or are they outsourced?

Radiation safety (y/n)	Conducted in-house (If so, please provide the number of full-time equivalents providing these services in your centre)	Outsourced

Radioactive Waste Adviser (RWA)		Y
Radiation Protection Adviser (RPA)	Y (1WTE Imaging, 1WTE RT)	
Medical Physics Expert (MPE)	Y 2.6WTE Imaging MPE	

### Question 8

Please complete the table below:

Dosimetry	(y/n)	If yes, what is the schedule after each administration?	If yes, is this analysed in-house or outsourced?
Is dosimetry performed for radium-223 dichloride prostate cancer patients?	N (weight based admin)		

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

<https://forms.office.com/r/eLzHXi49Ea>



Kind Regards,

The Information Governance Team  
Contact Email: [ccf-tr.foi@nhs.net](mailto:ccf-tr.foi@nhs.net)